Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AL58805 + Lomustine + Temozolomide |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AL58805 | AL 58805|AL-58805 | mTOR Inhibitor 52 PI3K Inhibitor (Pan) 44 | Limited information is currently available on AL58805, a putative dual-target PI3K/mTOR inhibitor (Sep 2026). | |
| Lomustine | Belustine | CCNU | ||
| Temozolomide | Temodar | Methazolastone|TMZ | Chemotherapy - Alkylating 18 | Temodar (temozolomide) is a dacarbazine analog and cytotoxic alkylating agent (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07811297 | Phase Ib/II | Anlotinib AL58805 + Anlotinib AL58805 + Lomustine + Temozolomide | A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers | Not yet recruiting | USA | 0 |